Viyash Scientific Limited is reshaping its board with the addition of two Carlyle-backed voices. In a meeting held on April 22, 2026, the company approved the appointment of Amit Jain and Abhiroop Jayanthi as Additional Directors, both designated as Non-Executive, Non-Independent Directors. Their appointments, which are to hold office subject to shareholder approval and liable to retire by rotation, reflect the company’s strategy to deepen investor alignment at the board level.
Amit Jain brings a rich private-equity pedigree to Viyash, serving as a Partner and Head of Carlyle India Advisors. He oversees Carlyle’s India operations and portfolio activities across technology, consumer, and industrial sectors, with prior leadership stints at Blackstone, McKinsey, and Unilever. Abhiroop Jayanthi, a Managing Director in Carlyle’s Asia Private Equity team, focuses on investments in healthcare, life sciences, and industrials, drawing on 15 years of private-equity experience and leadership roles at Bain Capital. Both appointments are framed as additions to the board to guide the company through a growth phase, with Carlyle maintaining a strong governance and strategic presence.
Separately, the board approved a revised ESOP pool under the ESOP 2026 plan, designating 1,30,98,000 stock options for grant. This adjusts the total option pool from the previously proposed 1,34,75,000 options, signaling a calibrated approach to talent incentives aligned with the company’s evolving strategy.